Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention

Autores
Sookoian, Silvia Cristina; Pirola, Carlos José
Año de publicación
2017
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
We read with great interest the article of Ajmera et al. (1) reporting on the relationship between bio- markers and the histological disease spectrum of nonal- coholic fatty liver disease (NAFLD) in a large population of well-characterized patients from the Non- alcoholic Steatohepatitis Clinical Research Network. The researchers found a significant association between circulating levels of total plasminogen activator inhibitor 1 (tPAI1) and the presence of nonalcoholic steatohepa- titis, which was independent of clinical confounding factors. (1) The clinical value of this result should be highlighted, also having important implications for tai- loring pharmacological interventions.
Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
Fil: Pirola, Carlos José. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
Materia
Nafld
Nash
Biomarkers
Metabolic Syndrome
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/49789
Acceder
id CONICETDig_5900ac7e0ab869565ebf2c64014a8e39
oai_identifier_str oai:ri.conicet.gov.ar:11336/49789
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological interventionSookoian, Silvia CristinaPirola, Carlos JoséNafldNashBiomarkersMetabolic Syndromehttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3We read with great interest the article of Ajmera et al. (1) reporting on the relationship between bio- markers and the histological disease spectrum of nonal- coholic fatty liver disease (NAFLD) in a large population of well-characterized patients from the Non- alcoholic Steatohepatitis Clinical Research Network. The researchers found a significant association between circulating levels of total plasminogen activator inhibitor 1 (tPAI1) and the presence of nonalcoholic steatohepa- titis, which was independent of clinical confounding factors. (1) The clinical value of this result should be highlighted, also having important implications for tai- loring pharmacological interventions.Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; ArgentinaFil: Pirola, Carlos José. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; ArgentinaJohn Wiley & Sons Inc2017-04-13info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/49789Sookoian, Silvia Cristina; Pirola, Carlos José; Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention; John Wiley & Sons Inc; Hepatology (Baltimore, Md.); 65; 4; 13-4-2017; 1417-14190270-9139CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1002/hep.28866info:eu-repo/semantics/altIdentifier/url/https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.28866info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:35:35Zoai:ri.conicet.gov.ar:11336/49789instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:35:36.172CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention
title Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention
spellingShingle Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention
Sookoian, Silvia Cristina
Nafld
Nash
Biomarkers
Metabolic Syndrome
title_short Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention
title_full Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention
title_fullStr Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention
title_full_unstemmed Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention
title_sort Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention
dc.creator.none.fl_str_mv Sookoian, Silvia Cristina
Pirola, Carlos José
author Sookoian, Silvia Cristina
author_facet Sookoian, Silvia Cristina
Pirola, Carlos José
author_role author
author2 Pirola, Carlos José
author2_role author
dc.subject.none.fl_str_mv Nafld
Nash
Biomarkers
Metabolic Syndrome
topic Nafld
Nash
Biomarkers
Metabolic Syndrome
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv We read with great interest the article of Ajmera et al. (1) reporting on the relationship between bio- markers and the histological disease spectrum of nonal- coholic fatty liver disease (NAFLD) in a large population of well-characterized patients from the Non- alcoholic Steatohepatitis Clinical Research Network. The researchers found a significant association between circulating levels of total plasminogen activator inhibitor 1 (tPAI1) and the presence of nonalcoholic steatohepa- titis, which was independent of clinical confounding factors. (1) The clinical value of this result should be highlighted, also having important implications for tai- loring pharmacological interventions.
Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
Fil: Pirola, Carlos José. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
description We read with great interest the article of Ajmera et al. (1) reporting on the relationship between bio- markers and the histological disease spectrum of nonal- coholic fatty liver disease (NAFLD) in a large population of well-characterized patients from the Non- alcoholic Steatohepatitis Clinical Research Network. The researchers found a significant association between circulating levels of total plasminogen activator inhibitor 1 (tPAI1) and the presence of nonalcoholic steatohepa- titis, which was independent of clinical confounding factors. (1) The clinical value of this result should be highlighted, also having important implications for tai- loring pharmacological interventions.
publishDate 2017
dc.date.none.fl_str_mv 2017-04-13
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/49789
Sookoian, Silvia Cristina; Pirola, Carlos José; Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention; John Wiley & Sons Inc; Hepatology (Baltimore, Md.); 65; 4; 13-4-2017; 1417-1419
0270-9139
CONICET Digital
CONICET
url http://hdl.handle.net/11336/49789
identifier_str_mv Sookoian, Silvia Cristina; Pirola, Carlos José; Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention; John Wiley & Sons Inc; Hepatology (Baltimore, Md.); 65; 4; 13-4-2017; 1417-1419
0270-9139
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1002/hep.28866
info:eu-repo/semantics/altIdentifier/url/https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.28866
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv John Wiley & Sons Inc
publisher.none.fl_str_mv John Wiley & Sons Inc
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613110017556480
score 13.069144

Publicaciones similares